Abstract:HIV envelope transmembrane glycoproteins gp41 (HIV-1) and gp36 (HIV-2) present high variability and play a key role in the HIV-host cell membrane's fusion, as a target for human broadly neutralizing antibodies (bnAbs) and drugs. Thus, a better knowledge of amino acid (aa) conservation across structural domains and HIV variants can help to identify conserved targets to direct new therapeutic and diagnostic strategies. All available gp41/gp36 nucleotide sequences were downloaded from Los Alamos National Laboratory (LANL) HIV Sequence Database, selecting 17,078 sequences ascribed to HIV-1 and HIV-2 variants with ≥3 sequences. After aligning and translating into aa with MEGAv6.0, an in-house bioinformatics program (EpiMolBio) was used to identify the most conserved aa and the aa changes that were specific for each variant (V-markers) vs. HXB2/BEN (HIV-1/HIV-2) reference sequence. We analyzed the presence of specific aa changes among V-markers affecting infectivity, gp41 structure, function, or resistance to the enfuvirtide viral fusion inhibitor (T-20). We also inferred the consensus sequences per HIV variant, describing in each HIV-1 group (M, N, O, P) the conservation level along the complete gp41 per structural domain and locating in each binding site the anti-gp41 human Abs (bnAbs and non bnAbs) described in LANL. We found 38.3/59.7% highly conserved aa present in ≥90% of the 16,803/275 gp41/gp36 sequences ascribed to 105/3 HIV-1/HIV-2 variants, with 9/12.6% of them showing complete conservation across LANL sequences. The fusion peptide, its proximal region, the N-heptad repeat, and the membrane-proximal external region were the gp41 domains with ≥84% of conserved aa in the HIV-1 consensus sequence, the target of most Abs. No natural major resistance mutations to T-20 were observed. Our results show, for the first time, a complete conservation study of gp41/gp36 per variant in the largest panel of HIV variants analyzed to date, providing useful information for a more rational design of drugs, vaccines, and molecular detection tests targeting the HIV transmembrane glycoprotein.

HIV-1 Gp140 Epitope Recognition is Influenced by Immunoglobulin DH Gene Segment Sequence

Differential Reactivity of Germ Line Allelic Variants of a Broadly Neutralizing HIV-1 Antibody to a Gp41 Fusion Intermediate Conformation.

Neutralizing Epitopes in the Membrane-Proximal Region of Hiv-1 Gp41: Genetic Variability and Co-Variation

Envelope Deglycosylation Enhances Antigenicity of HIV-1 Gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies

Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads

Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies

Structural Basis for Unusual TCR CDR3β Usage Against an Immunodominant HIV-1 Gag Protein Peptide Restricted to an HLA-B*81:01 Molecule

Recognition Of Synthetic Glycopeptides By Hiv-1 Broadly Neutralizing Antibodies And Their Unmutated Ancestors

Structural Basis for Unusual TCR CDR3 beta Usage Against an Immunodominant HIV-1 Gag Protein Peptide Restricted to an HLA-B*81:01 Molecule

Epitopes Immediately below the Base of the V3 Loop of Gp120 As Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-infected Individuals.

Genetic Variability of Principal Neutralizing Determinants on HIV-1 Gp41 and Its Correlation with Subtypes.

Conserved Hiv-1 Epitopes Continuously Elicit Subdominant Cytotoxic T-Lymphocyte Responses

Recognition of HIV-1 Peptides by Host CTL is Related to HIV-1 Similarity to Human Proteins.

E104 Identification of Three Distinct Epitope Regions in the V2 Portion of Gp120

Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes.

Antibody Light-Chain-restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial is Phylogenetically Conserved.

Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240

Residues in the Gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by Gp120-Directed Inhibitors.

Identification of a Synthetic Peptide That Mimics an HIV Glycoprotein 120 Envelope Conformational Determinant Exposed Following Ligation of Glycoprotein 120 by CD4.

HIV Transmembrane Glycoprotein Conserved Domains and Genetic Markers Across HIV-1 and HIV-2 Variants

The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals